JAZZ (Jazz Pharmaceuticals, Inc.) Stock Analysis - Analyst Ratings

Jazz Pharmaceuticals, Inc. (JAZZ) is a publicly traded Healthcare sector company. As of May 21, 2026, JAZZ trades at $239.96 with a market cap of $14.40B and a P/E ratio of 26.45. JAZZ moved +0.70% today. Year to date, JAZZ is +37.05%; over the trailing twelve months it is +115.29%. Its 52-week range spans $95.49 to $242.18. Analyst consensus is strong buy with an average price target of $241.43. Rallies surfaces JAZZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate JAZZ?

15 analysts cover JAZZ: 0 strong buy, 14 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $241.43.

JAZZ Key Metrics

Key financial metrics for JAZZ
MetricValue
Price$239.96
Market Cap$14.40B
P/E Ratio26.45
EPS$9.06
Dividend Yield0.00%
52-Week High$242.18
52-Week Low$95.49
Volume7
Avg Volume0
Revenue (TTM)$4.07B
Net Income$560.12M
Gross Margin0.00%

JAZZ Analyst Consensus

15 analysts cover JAZZ: 0 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $241.43.

Latest JAZZ News

Recent JAZZ Insider Trades

  • COZADD BRUCE C sold 6.00K (~$1.22M) on May 1, 2026.
  • COZADD BRUCE C sold 3.68K (~$700.78K) on Apr 1, 2026.
  • COZADD BRUCE C sold 2.29K (~$437.63K) on Apr 1, 2026.

Common questions about JAZZ

What do analysts rate JAZZ?
15 analysts cover JAZZ: 0 strong buy, 14 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $241.43.
Does Rallies show JAZZ price targets?
Yes. Rallies tracks JAZZ analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is JAZZ research on Rallies investment advice?
No. Rallies provides research, data, and educational context for JAZZ. It does not provide personalized investment advice.
JAZZ

JAZZ